Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,090 | 1,152 | 21:09 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.08. | Saniona AB: Saniona publishes its interim report for the second quarter of 2025 | 70 | GlobeNewswire (Europe) | Three Months Ended June 30, 2025 (2024)Six Months Ended June 30, 2025 (2024)Revenue was SEK 9.3 M (8.0 M)Revenue was SEK 19.1 M (14.1 M)Operating profit/loss was SEK -25.9 M (-16.0 M)Operating profit/loss... ► Artikel lesen | |
21.08. | JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug | 1 | Zacks | ||
21.08. | Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug | 3 | MedCity News | ||
20.08. | Jazz Pharmaceuticals, Saniona Enter Exclusive Agreement | 2 | Contract Pharma | ||
20.08. | Jazz pays Saniona $42.5M to add preclinical prospect to epilepsy ensemble | 3 | FierceBiotech | ||
20.08. | Jazz Pharmaceuticals enters exclusive licensing deal with Saniona | 5 | Seeking Alpha | ||
SANIONA Aktie jetzt für 0€ handeln | |||||
20.08. | Jazz pharmaceuticals acquires rights to Saniona's epilepsy drug candidate | 2 | Investing.com | ||
20.08. | Saniona AB: Saniona Enters Exclusive Licensing Agreement with Jazz Pharmaceuticals to Develop and Commercialize SAN2355 | 186 | GlobeNewswire (Europe) | Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales
Jazz obtains exclusive worldwide rights to... ► Artikel lesen | |
28.05. | Saniona AB: Bulletin from the Saniona AB annual shareholders' meeting on May 28, 2025 | 140 | GlobeNewswire (Europe) | Today, on May 28, 2025, the annual shareholders' meeting was held in Saniona AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and distribution of the company's... ► Artikel lesen | |
12.05. | Saniona AB: Saniona appoints Johnny Stilou as Chief Financial Officer | 174 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the appointment of Johnny Stilou as Chief Financial Officer, effective immediately. He brings more than 25 years of... ► Artikel lesen | |
10.04. | Saniona - Broad pipeline to address neurological conditions | 402 | Edison Investment Research | Saniona is a European pioneer in ion channel drug discovery. Internally, it is primarily focused on its preclinical epilepsy pipeline: SAN2355 (for focal/generalised epilepsy) and SAN2219 (for acute... ► Artikel lesen | |
28.03. | Saniona's CSO to "We are on track with SAN2219" | 2 | Cision News | ||
26.03. | Saniona's CEO to "The TO4 proceeds give us flexibility to secure the best deals" | 2 | Cision News | ||
26.03. | Saniona AB: Saniona initiates scale-up and manufacturing of toxicology batches for SAN2219, a potential new therapy for epilepsy | 419 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the initiation of scale-up and manufacturing of toxicology batches for SAN2219, advancing the program toward clinical... ► Artikel lesen | |
11.03. | Saniona AB: Saniona and Boehringer Ingelheim extend research collaboration with one year | 515 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that the ongoing ion channel research collaboration with Boehringer Ingelheim has been extended with one year.
"The... ► Artikel lesen | |
10.03. | Saniona AB: Saniona Appoints Pierandrea Muglia, M.D., as Chief Medical Officer | 149 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the appointment of Pierandrea Muglia, M.D., as Chief Medical Officer. Dr. Muglia brings more than 30 years of experience... ► Artikel lesen | |
03.03. | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study | 412 | Business Wire | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study... ► Artikel lesen | |
27.02. | Saniona AB: Saniona publishes its year-end report for 2024 | 168 | GlobeNewswire (Europe) | Three Months Ended December 31, 2024 (2023)Twelve Months Ended December 31, 2024 (2023)Revenue was SEK 313.4 M (5.4 M)Revenue was SEK 334.7 M (16.8 M)Operating profit/loss was SEK 290.4 M (-19.8 M)Operating... ► Artikel lesen | |
28.11.24 | Saniona AB: Saniona publishes its interim report for the third quarter of 2024 | 218 | GlobeNewswire (Europe) | Three Months Ended September 30, 2024 (2023)Nine Months Ended September 30, 2024 (2023)Revenue was SEK 7.2 M (5.5 M)Revenue was SEK 21.3 M (11.5 M)Operating profit/loss was SEK -18.9 M (-18.4 M)Operating... ► Artikel lesen | |
14.10.24 | Saniona AB: Saniona Ion Channel Research Collaboration with Boehringer Ingelheim Reaches Milestone | 539 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the lead optimization... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 5,810 | -1,02 % | INSIDERALARM bei Evotec! Valneva mit neuem KURSZIEL! Vidac Pharma Aktie bald mit neuem ALLZEITHOCH? | Endlich! Bei Evotec sorgen Insider für ein wichtiges Signal. Die Aktie reagiert zwar noch nicht, aber mittelfristig könnte sich dies als Kaufsignal herausstellen. Derzeit herrscht noch Skepsis. Bullish... ► Artikel lesen | |
PAION | 0,015 | -40,00 % | Paion Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
NANOREPRO | 1,800 | 0,00 % | HV-Termine: Hauptversammlungen u.a. bei Baywa, Circus, Daldrup, Laiqon, NanoRepro, Pyramid, Umweltbank | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
4SC | 1,100 | +6,80 % | PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025 | DJ PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Planegg-Martinsried (pta000/08.08.2025/07:30... ► Artikel lesen | |
PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
BRAIN BIOTECH | 2,200 | -2,22 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech ernennt Johan Jansén-Storbacka zum Executive Vice President BRAINBiocatalysts für den Bereich Enzymprodukte | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Personalie
BRAIN Biotech ernennt Johan Jansén-Storbacka zum Executive Vice President BRAINBiocatalysts für den Bereich Enzymprodukte... ► Artikel lesen | |
AAP IMPLANTATE | 1,640 | +0,61 % | EQS-DD: aap Implantate AG: Nino Buckow, Verkauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
02.09.2025 / 09:54... ► Artikel lesen | |
BIOXXMED | 0,300 | 0,00 % | PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025 | DJ PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
bioXXmed AG: Ergebnis für... ► Artikel lesen | |
CLINUVEL | 6,020 | -1,39 % | Dividendenbekanntmachungen (04.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADMIRAL GROUP PLC GB00B02J6398 1,15 GBP 1,3255 EUR AEGON LTD ADR US0076CA1045 0,2206 USD 0,1891 EUR AMCOR PLC CDIS AU000000AMC4 0... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,441 | -2,26 % | Sangamo stock holds Buy rating at H.C. Wainwright on positive Fabry disease data | ||
BIO-GATE | 0,900 | 0,00 % | EQS-DD: Bio-Gate AG: Karl Richter, Zeichnung von Wandelschuldverschreibungen | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
21.08.2025 / 17:58... ► Artikel lesen | |
COSCIENS BIOPHARMA | 2,220 | 0,00 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
EDITAS MEDICINE | 2,330 | -1,60 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen |